Dr. Angelo Anthony Ciliberti Jr., MD

Dr. Ciliberti practices at Norton Women's and Children's Hospital-Operating Room - HOPD in Louisville, Kentucky.

Dr. Ciliberti's NPI, 1811428964, was assigned on March 21, 2017. Dr. Ciliberti holds Kentucky license 56690.

Dr. Ciliberti's primary practice is Norton Women's and Children's Hospital-Operating Room - HOPD, at 4001 Dutchmans Ln, Louisville, KY 40207.

Dr. Ciliberti's primary practice is Norton Women's and Children's Hospital-Operating Room - HOPD in Louisville, Kentucky. Dr. Ciliberti is also affiliated with Norton Hospital. The medical group on file is Norton Community Medical Associates. Dmand AI also links Dr. Ciliberti to 1 more group practice or clinic, 1 therapy and rehab clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ciliberti practices, 4 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Ciliberti's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dmand AI has Dr. Ciliberti's licenses on file in 2 states: Kentucky and Illinois.

CMS data shows 656 Medicare services from Dr. Ciliberti across 6 procedure codes in 2024, for 189 Medicare patients. Medicare paid $33,302 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 189 Medicare patients who saw Dr. Ciliberti in 2024. The largest group is 65 to 74, with 83 patients. 75% of them have arthritis, and 72% have high blood pressure. 16% are also on Medicaid. Their average risk score is 1.37, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Ciliberti's median patient age at 67, with 68% women.

In 2024, Dr. Ciliberti wrote 1,332 Medicare Part D claims for 306 patients. 77% of them were for generic drugs. CMS names the drug for 1,192 of them, across 16 drugs with 11 or more claims each, at $1,649,471 in total drug cost. In 2023, CMS named 622 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Ciliberti for performance year 2024, reported as part of a group. Dr. Ciliberti accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 8 general payments to Dr. Ciliberti from 7 drug and device companies from 2021 to 2025. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $244.